Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...
Cancer Epidemiol Biomarkers Prev (2009) 18 (6): 1740–1745. The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to ...
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex Open Access Linjie Yuan; Wenzhi Ji; Brendan G. Dwyer; Joey Lu; Jing Bian; ...
You do not currently have access to this content.
Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital (Medical School of Chinese PLA), Beijing, China.
Mol Cancer Ther (2023) 22 (12_Supplement): PR010. Methods: Patients with previously treated, advanced KRAS G12X mutant solid tumors were enrolled at escalating doses of single agent RMC-6236 ...
Cancer Res (2026) 86 (5_Supplement_2): PR002.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results